Mechanism study of goldenseal-associated DNA damage

Toxicology Letters

Volumn 221, Issue 1, 2013, Pages 64-72

  Chen, Si ^a   Wan, Liqing ^a,b   Couch, Letha ^a   Lin, Haixia ^a   Li, Yan ^a   Dobrovolsky, Vasily N ^a   Mei, Nan ^a   Guo, Lei ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Berberine; Cell cycle arrest; Comet assay; DNA damage; Goldenseal; Topoisomerase I; Topoisomerase II; H2A.X

Indexed keywords

ALKALOID; BERBERINE; BERBERINE DERIVATIVE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); H2AFX PROTEIN, HUMAN; HISTONE; MUTAGENIC AGENT; PALMATINE; PLANT EXTRACT; SMALL INTERFERING RNA;

ARTICLE; CELL STRAIN HEPG2; CHEMISTRY; COMET ASSAY; DNA DAMAGE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; HYDRASTIS; LIVER CELL; METABOLISM; STRUCTURE ACTIVITY RELATION; Γ-H2A.X;

BERBERINE; COMET ASSAY; DNA DAMAGE; GOLDENSEAL; TOPOISOMERASE; Γ-H2A.X;

ALKALOIDS; BERBERINE; BERBERINE ALKALOIDS; COMET ASSAY; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; HEP G2 CELLS; HEPATOCYTES; HISTONES; HUMANS; HYDRASTIS; MUTAGENS; PLANT EXTRACTS; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP;

MLCS; MLOWN;

EID: 84884171286     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.05.641     Document Type: Article

References (60)

1. Bartek, J., Lukas, J., Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3 (2003), 421–429.
2. Boos, G., Stopper, H., Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116 (2000), 7–16.
3. Champoux, J.J., DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70 (2001), 369–413.
4. Chehab, N.H., Malikzay, A., Appel, M., Halazonetis, T.D., Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14 (2000), 278–288.
5. Chen, W., Miao, Y.Q., Fan, D.J., Yang, S.S., Lin, X., Meng, L.K., Tang, X., Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech 12 (2011), 705–711.
6. CITES, 1997. Amendments to Appendices I and II of the Convention on Internation Trade in Endangered Species and Wild Fauna and Flora.
7. Deng, Y., Liao, Q., Li, S., Bi, K., Pan, B., Xie, Z., Simultaneous determination of berberine, palmatine and jatrorrhizine by liquid chromatography-tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of coptis-evodia herb couple. J Chromatogr B Analyt Technol Biomed Life Sci 863 (2008), 195–205.
8. Dunnick, J.K., Singh, B., Nyska, A., Peckham, J., Kissling, G.E., Sanders, J.M., Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol Pathol 39 (2011), 398–409.
9. Dykens, J.A., Jamieson, J.D., Marroquin, L.D., Nadanaciva, S., Xu, J.J., Dunn, M.C., Smith, A.R., Will, Y., In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103 (2008), 335–345.
10. Ezoe, S., Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9 (2012), 2444–2453.
11. Fu, P.P., Xia, Q., Guo, L., Yu, H., Chan, P.C., Toxicity of kava kava. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 26 (2008), 89–112.
12. Fortune, J.M., Osheroff, N., Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64 (2000), 221–253.
13. Gartel, A.L., Radhakrishnan, S.K., Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65 (2005), 3980–3985.
14. Gatei, M., Sloper, K., Sorensen, C., Syljuasen, R., Falck, J., Hobson, K., Savage, K., Lukas, J., Zhou, B.B., Bartek, J., Khanna, K.K., Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278 (2003), 14806–14811.
15. Gatto, B., Sanders, M.M., Yu, C., Wu, H.Y., Makhey, D., LaVoie, E.J., Liu, L.F., Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56 (1996), 2795–2800.
16. Govindan, M., Govindan, G., A convenient method for the determination of the quality of goldenseal. Fitoterapia 71 (2000), 232–235.
17. Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.L., Green, B., Deng, H., Kaput, J., Ning, B., Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes. Drug Metab Dispos 39 (2011), 528–538.
18. Guo, L., Shi, Q., Fang, J.L., Mei, N., Ali, A.A., Lewis, S.M., Leakey, J.E., Frankos, V.H., Review of usnic acid and Usnea barbata toxicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 26 (2008), 317–338.
19. Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P.C., Fu, P., Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol 47 (2009), 433–442.
20. Guo, L., Mei, N., Xia, Q., Chen, T., Chan, P.C., Fu, P.P., Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 28 (2010), 60–87.
21. Guo, L., Zhang, L., Sun, Y., Muskhelishvili, L., Blann, E., Dial, S., Shi, L., Schroth, G., Dragan, Y.P., Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10 (2006), 349–360.
22. Hamon, N.W., Goldenseal. CanPharmJ 123 (1990), 508–510.
23. Harker, W.G., Slade, D.L., Drake, F.H., Parr, R.L., Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30 (1991), 9953–9961.
24. Hijiya, N., Ness, K.K., Ribeiro, R.C., Hudson, M.M., Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 115 (2009), 23–35.
25. Ivashkevich, A., Redon, C.E., Nakamura, A.J., Martin, R.F., Martin, O.A., Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 327 (2012), 123–133.
26. Jeon, Y.W., Jung, J.W., Kang, M., Chung, I.K., Weontae, L., NMR Studies on Antitumor Drug Candidates, Berberine and Berberrubine. Bull Korean Chem Soc 23 (2002), 391–394.
27. Kang, M.R., Chung, I.K., Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. Mol Pharmacol 61 (2002), 879–884.
28. Kettmann, V., Kost'alova, D., Holtje, H.D., Human topoisomerase I poisoning: docking protoberberines into a structure-based binding site model. J Comput Aided Mol Des 18 (2004), 785–796.
29. Kim, S.A., Kwon, Y., Kim, J.H., Muller, M.T., Chung, I.K., Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Biochemistry 37 (1998), 16316–16324.
30. Kobayashi, Y., Yamashita, Y., Fujii, N., Takaboshi, K., Kawakami, T., Kawamura, M., Mizukami, T., Nakano, H., Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med 61 (1995), 414–418.
31. Larsen, A.K., Escargueil, A.E., Skladanowski, A., Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99 (2003), 167–181.
32. Li, T.K., Bathory, E., LaVoie, E.J., Srinivasan, A.R., Olson, W.K., Sauers, R.R., Liu, L.F., Pilch, D.S., Human topoisomerase I poisoning by protoberberines: potential roles for both drug-DNA and drug-enzyme interactions. Biochemistry 39 (2000), 7107–7116.
33. Li, Y., Couch, L., Higuchi, M., Fang, J.L., Guo, L., Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicol Sci 127 (2012), 582–591.
34. Li, Y., Luan, Y., Qi, X., Li, M., Gong, L., Xue, X., Wu, X., Wu, Y., Chen, M., Xing, G., Yao, J., Ren, J., Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Toxicol Sci 118 (2010), 435–443.
35. Liu, Z.H., Zeng, S., Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes. Toxicol Lett 187 (2009), 131–136.
36. Matsuoka, S., Huang, M., Elledge, S.J., Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998), 1893–1897.
37. Mazzini, S., Bellucci, M.C., Mondelli, R., Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT)(2). Bioorg Med Chem 11 (2003), 505–514.
38. McClendon, A.K., Osheroff, N., DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623 (2007), 83–97.
39. Mei, N., Lee, J., Sun, X., Xing, J.Z., Hanson, J., Le, X.C., Weinfeld, M., Genetic predisposition to the cytotoxicity of arsenic: the role of DNA damage and ATM. FASEB J 17 (2003), 2310–2312.
40. NatureServe, NatureServe Explorer: http://www.natureserve.org/explorer/servlet/NatureServe?searchName = Hydrastis + canadensis+.
41. Nguyen, K.C., Willmore, W.G., Tayabali, A.F., 2013. Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells. Toxicology 306 C, 114-123.
42. Niculescu, A.B. 3rd, Chen, X., Smeets, M., Hengst, L., Prives, C., Reed, S.I., Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18 (1998), 629–643.
43. NTP, 2009. NTP technical report on the toxicity and carcinogenesis studies of goldenseal root power in F344/N rats and B6C3F1 mice. NTP TR 562, NIH Publication No09-5903, National Toxicology Program.
44. Park, H.S., Lim, E., Sung, Y.H., Kang, M., Chung, I.K., Chaejoon, C., Weontae, L., DNA Binding Mode of the Isoquinoline Alkaloid Berberine with the Deoxyoligonucleotide d(GCCGTCGTTTTACA)2. Bull Korean Chem Soc 125 (2004), 539–544.
45. Qin, Y., Pang, J.Y., Chen, W.H., Zhao, Z.Z., Liu, L., Jiang, Z.H., Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids. Chem Biodivers 4 (2007), 481–487.
46. Qiu, F., Zhu, Z., Kang, N., Piao, S., Qin, G., Yao, X., Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 36 (2008), 2159–2165.
47. Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S., Bonner, W.M., DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273 (1998), 5858–5868.
48. Sanchez, Y., Wong, C., Thoma, R.S., Richman, R., Wu, Z., Piwnica-Worms, H., Elledge, S.J., Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277 (1997), 1497–1501.
49. Seiter, K., Feldman, E.J., Sreekantaiah, C., Pozzuoli, M., Weisberger, J., Liu, D., Papageorgio, C., Weiss, M., Kancherla, R., Ahmed, T., Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15 (2001), 963–970.
50. Shiloh, Y., ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11 (2001), 71–77.
51. Tebbi, C.K., London, W.B., Friedman, D., Villaluna, D., De Alarcon, P.A., Constine, L.S., Mendenhall, N.P., Sposto, R., Chauvenet, A., Schwartz, C.L., Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25 (2007), 493–500.
52. Tsai, P.L., Tsai, T.H., Hepatobiliary excretion of berberine. Drug Metab Dispos 32 (2004), 405–412.
53. Vos, S.M., Tretter, E.M., Schmidt, B.H., Berger, J.M., All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12 (2011), 827–841.
54. Waldman, T., Kinzler, K.W., Vogelstein, B., p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55 (1995), 5187–5190.
55. Wei, W., Zhang, C., Liu, A.L., Xie, S.H., Chen, X.M., Lu, W.Q., PCB126 enhanced the genotoxicity of BaP in HepG2 cells by modulating metabolic enzyme and DNA repair activities. Toxicol Lett 189 (2009), 91–95.
56. Wilstermann, A.M., Osheroff, N., Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 3 (2003), 321–338.
57. Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M., Nakano, H., Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31 (1992), 12069–12075.
58. Ye, M., Fu, S., Pi, R., He, F., Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol 61 (2009), 831–837.
59. Zeng, X.H., Zeng, X.J., Li, Y.Y., Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92 (2003), 173–176.
60. Zhao, H., Piwnica-Worms, H., ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21 (2001), 4129–4139.